미래가치를 창출하는 글로컬 산학일체 혁신대학
Let’s get through , COVID-19
By Joung In-young Reporter, Sophomore of Electronics Control Engineering
Many changes in daily life have come due to COVID-19, which has been going
on for more than a year. Let’s find out what’s happened so far and what the plan is for the future.
COVID-19 vaccine in the global pharmaceutical industry.
The global pharmaceutical industry is working together to develop technologies that can end COVID-19. The Korea International Pharmaceutical Industry Association (KRPIA) has developed a vaccine in a surprisingly short time of one year since the COVID hit the world. The KRPIA said seven vaccines have been fully approved for use worldwide. According to the COVID-19 vaccine and treatment status of the U.S. Pharmaceutical Association, a total of nine vaccines and treatments have been approved for emergency use and licensed in the U.S., 81 global vaccines and 544 global treatments are currently being tested, with a total of 1,613 clinical trials.
COVID-19 vaccine development
2-1) Pfizer and German co-developed vaccine BioNTech.
Starting with the U.K., which announced the world's first approval for use on
December 2, 2020, it received emergency approval from the U.S. Food and Drug
Administration (FDA) on December 11. This vaccine has been shown to have 95
percent prevention effect in Phase III clinical trials. Pfizer and BioNTech
have expanded their plant for mass production of vaccines and expect to be able
to manufacture 2 billion doses worldwide by the end of 2021.
Moderna was the second FDA-approved emergency used on December 18,
2020, following the Pfizer vaccine. Moderna launched the first clinical trial for
COVID-19, and developed the vaccine in collaboration with the National Institute of
Allergy and Infectious Diseases (NIH) with $1 billion in aid, based on the U.S.
government’'s vaccine development project “Super-Fast Operation.” It is expanding
its investment to produce 1.4 billion doses in 2022.
On February 27, 2021, it was the third time that a vaccine was approved for emergency use as a COVID-19 vaccine by the U.S. FDA, and it is the first vaccine to demonstrate safety and efficacy with a single dose. Johnson & Johnson (J&J) said it aims to produce 1 billion doses of the vaccine in 2021.
AstraZeneca is a COVID-19 vaccine developed in collaboration with the Oxford Jenner Institute in the UK. On February 10 last year, the Ministry of Food and Drug Safety gave its first permission in the UK to prevent COVID-19 caused by the SARS-CoV-2 virus in all adults aged 18 or older. It is not profitable during the COVID-19 pandemic. They are also working with various governments and major health organizations, such as the World Health Organization (WHO), to ensure rapid vaccine supplies worldwide.
Treatments and vaccines
Major symptoms include the administration of antibiotics to prevent antiviral
drugs or secondary infections. Some of the patients were found to be able to heal with
autoimmune without antiviral medication. In some cases, the virus lasts three to four
weeks without symptoms. Also, even after symptoms improve, in rare cases, the virus may reactivate, so even if the treatment is over, it is recommended to self-isolate for
at least two weeks.
3-2) Characteristics of Vaccine
So far, we have looked into COVID-19 and domestic countermeasures. I would like to
remind you once again that the number of confirmed cases is constantly decreasing. Don't let your guard down! Wearing a mask is a must!